Moderna Inc. continues to revolutionize the health industry with its mRNA medicines. Good news stem from promising results in preliminary animal studies involving their new mRNA vaccines, such as the Mpox vaccine and upcoming therapies, seem hopeful for deadly diseases like cancer and norovirus. Moderna’s ongoing success story is not without its hurdles, as the Respiratory Syncytial Virus (RSV) vaccine trials faced a pause due to safety concerns calling for more research. In the stock market, although the current landscape appears challenging with the company witnessing a dip, bullish predictions hint at a bounce back. On the legal side, GlaxoSmithKline has accused Moderna of patent infringements around mRNA vaccines and Northwestern University has filed a lawsuit against Moderna over Spikavax vaccine. Despite this, Moderna has extended its partnership with Merck for cancer therapy platform development and landed a $176M US government deal to develop an mRNA bird flu pandemic vaccine. Data from late-stage trials of a combination Covid-flu vaccine appear positive, reinforcing Moderna’s role as a pioneer in mRNA vaccine and respiratory health.
Moderna MRNA News Analytics from Fri, 01 Mar 2024 08:00:00 GMT to Fri, 20 Dec 2024 17:45:39 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -1
